Imatinib mesylate may improve fasting blood glucose in diabetic Ph+ chronic myelogenous leukemia patients responsive to treatment.
暂无分享，去创建一个
[1] S. Whittaker,et al. EORTC Cutaneous Lymphoma Task Force , 2002 .
[2] M. Baccarani,et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. , 2002, The New England journal of medicine.
[3] M Cascante,et al. Gleevec (STI571) influences metabolic enzyme activities and glucose carbon flow toward nucleic acid and fatty acid synthesis in myeloid tumor cells. , 2001, The Journal of biological chemistry.
[4] S. Baldwin,et al. Glucose transport regulation by p210 Bcr–Abl in a chronic myeloid leukaemia model , 2001, British journal of haematology.